Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) Research & Development (2016 - 2025)

Altimmune (ALT) has disclosed Research & Development for 16 consecutive years, with $15.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Research & Development fell 24.46% to $15.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $67.8 million, a 14.56% decrease, with the full-year FY2024 number at $82.2 million, up 24.97% from a year prior.
  • Research & Development was $15.0 million for Q3 2025 at Altimmune, down from $17.2 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $29.2 million in Q3 2021 to a low of $11.9 million in Q1 2021.
  • A 5-year average of $18.0 million and a median of $17.2 million in 2023 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: surged 125.51% in 2021, then plummeted 30.62% in 2022.
  • Altimmune's Research & Development stood at $20.2 million in 2021, then dropped by 4.98% to $19.2 million in 2022, then decreased by 11.84% to $16.9 million in 2023, then grew by 16.99% to $19.8 million in 2024, then dropped by 24.37% to $15.0 million in 2025.
  • Per Business Quant, the three most recent readings for ALT's Research & Development are $15.0 million (Q3 2025), $17.2 million (Q2 2025), and $15.8 million (Q1 2025).